

## Influenza vaccines: Evaluation of the safety profile

Claudia Maria Trombetta<sup>a,†</sup>, Elena Giancchetti<sup>b,†</sup>, and Emanuele Montomoli<sup>a,b</sup>

<sup>a</sup>Department of Molecular and Developmental Medicine, University of Siena, Siena, Italy; <sup>b</sup>VisMederi srl, Siena, Italy

### ABSTRACT

The safety of vaccines is a critical factor in maintaining public trust in national vaccination programs. Vaccines are recommended for children, adults and elderly subjects and have to meet higher safety standards, since they are administered to healthy subjects, mainly healthy children. Although vaccines are strictly monitored before authorization, the possibility of adverse events and/or rare adverse events cannot be totally eliminated.

Two main types of influenza vaccines are currently available: parenteral inactivated influenza vaccines and intranasal live attenuated vaccines. Both display a good safety profile in adults and children. However, they can cause adverse events and/or rare adverse events, some of which are more prevalent in children, while others with a higher prevalence in adults.

The aim of this review is to provide an overview of influenza vaccine safety according to target groups, vaccine types and production methods.

### ARTICLE HISTORY

Received 2 October 2017  
Revised 30 November 2017  
Accepted 23 December 2017

### KEYWORDS

adverse events; influenza vaccines; safety; vaccine types; age-groups

## Introduction

Vaccination is the most effective method of controlling seasonal influenza infections and the most important strategy for preventing possible pandemic events.<sup>1</sup> Influenza vaccines are recommended for children, adults and elderly subjects.<sup>2</sup> Since vaccines are mainly administered to healthy people, they need to comply with a higher safety standard. In addition, as they are used to immunize a considerable part of the population, rare adverse events (AEs) may affect a significant number of individuals.<sup>3,4</sup>

A “vaccine AE” or an “AE following immunization” is defined as “any untoward medical occurrence which occurs during administration of a vaccine or follows immunization and which does not necessarily have a causal relationship with the use of the vaccine. The adverse event may be any unfavorable or unintended sign, an abnormal laboratory finding, a symptom or a disease”.<sup>5</sup> AEs also include those events associated with vaccination errors and reactions correlated with anxiety and product quality defect.

The terms “adverse drug reaction” and “adverse vaccine reaction or effect” are both used to indicate that the development of the AE has a causal relationship with the medicinal product, as indicated by consistent scientific evidence.<sup>6</sup> The identification of potential serious adverse reactions during clinical trials can evoke significant changes in the manufacturing process, especially if these reactions are fatal or life-threatening; in such cases, regulators should be promptly informed. It is recommended that the old term “side effects”, which was used to indicate both favorable (positive) and unfavorable (negative) effects, should no longer be used, or at least not as a synonym

for the terms “adverse event” or “adverse reaction”.<sup>7</sup> Moreover, the terms “severe” and “serious” do not have the same meaning. Indeed, whereas the former is usually used to indicate the severity of a particular event, which may have minimal medical importance, the latter identifies the outcome of the patient or the measures required to deal with the reactions that threaten the patient’s life or functions; these serious reactions are subject to obligatory reporting.<sup>7</sup>

Before a vaccine is licensed, its safety is evaluated in different phases of clinical trials; it subsequently undergoes post-licensure surveillance.<sup>8</sup>

Vaccine safety may differ according to the target group, the genetic predisposition of the population and the type of vaccine.<sup>9</sup>

Although vaccines are strictly monitored before authorization, the possibility of AEs due to annual changes in vaccine formulations, vaccine administration patterns, environmental factors or genetic factors of the host cannot be totally eliminated. Consequently, annual post-licensure vaccine safety surveillance is fundamental.<sup>10</sup> With regard to extremely rare events (1 case every 10,000 vaccinations),<sup>11</sup> the relatively low number of cases available for analysis constitutes a study limitation. If no event of concern is registered in a study (i.e. a zero numerator is reported), it is necessary to conduct further investigations. Indeed, a zero numerator does not mean the absence of risk.<sup>12</sup> In the case of a vaccine, AEs can only be reliably identified after larger populations have been vaccinated. For this reason, post-marketing surveillance is fundamental. Recently, an increased incidence of narcolepsy was reported in six European countries following vaccination with Pandemrix against pandemic influenza A virus, A(H1N1)pdm09 (“swine flu”),

**CONTACT** Claudia Maria Trombetta  [trombetta@unisi.it](mailto:trombetta@unisi.it)  Department of Molecular and Developmental Medicine, Via Aldo Moro 2, 53100 Siena Italy.

<sup>†</sup>The authors contributed equally to this work.

© 2018 Claudia Maria Trombetta, Elena Giancchetti, and Emanuele Montomoli. Published with license by Taylor & Francis  
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (<http://creativecommons.org/licenses/by-nc-nd/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.

during the winter 2009–2010 (see below). The recent systematic review and meta-analysis conducted by Sarkanen and coll.<sup>13</sup> in order to investigate the incidence of narcolepsy related to H1N1 vaccination revealed that Pandemrix was the only vaccine associated with an increased risk. The relative risk of narcolepsy was 5- to 14-fold higher in children/adolescents and 2- to 7-fold higher in adults in the first year following immunization. Furthermore, investigations conducted in Finland and Sweden seemed to demonstrate that the risk of narcolepsy extended into the second year after vaccination, although further data are necessary to confirm this hypothesis. In addition to post-marketing surveillance, enhanced safety surveillance (ESS) is required by the European Medicines Agency (EMA) for all seasonal influenza vaccines, in order to improve the rapid detection of clinically significant changes in the safety profile of flu vaccines.<sup>14,15</sup> It is recommended that ESS is included in routine pharmacovigilance activities if the vaccine is used for the first time and is administered to all age-groups (e.g. subjects aged 6 months to 5 years, 6 to 12 years, 13 to 18 years,  $\geq 18$  years–65 years and  $> 65$  years).<sup>14</sup>

In Europe, vaccine safety is monitored by the Vaccine Adverse Event Surveillance and Communication (VAESCO) consortium, and in the United States by the Centers for Disease Control and Prevention (CDC) through the routine use of two surveillance systems: the Vaccine Adverse Event Reporting System (VAERS) and the Vaccine Safety Datalink (VSD).<sup>16</sup>

In addition to national surveillance organizations, the World Health Organization (WHO) has established a global system for international drug monitoring – the Uppsala Monitoring Center (UMC) and the Global Advisory Committee on Vaccine Safety (GACVS) – in order to address vaccine safety issues of potential global importance in a scientifically accurate manner.<sup>3,4,17</sup> The surveillance of influenza vaccine safety in terms of post-marketing adverse drug events is usually prompted by spontaneous reporting. While North America and Europe have the most advanced information systems for the assessment of drug safety upon licensing and population coverage, Asian countries are making good progress.<sup>18</sup>

The aim of this review is to provide an overview of vaccine safety according to target groups, vaccine types and production methods.<sup>9</sup>

## Vaccine types and production methods

The safety of vaccines is a critical factor in maintaining public trust in national vaccination programs. This is especially true of influenza vaccines, the composition of which needs to be evaluated twice a year in order to ensure antigenic matching between the viral strain contained in the vaccine and the circulating strain.<sup>19</sup> Two main types of influenza vaccines are currently available and are administered by different routes: parenteral inactivated influenza vaccines (IIVs) and intranasal live attenuated influenza vaccines (LAIVs). The former have been used for more than 50 years, are licensed for use in subjects aged  $\geq 6$  months and display a good safety profile; the latter are licensed in Europe for children from 2–17 years of age and induce a broader immune response involving both local and systemic antibody and T-cell responses.<sup>20</sup>

## Inactivated Influenza Vaccines

IIVs have been manufactured and used since 1940, and are the most common influenza vaccines. Until 2015, vaccine producers were required by EMA committee to perform annual clinical trials in order to evaluate both immunogenicity and safety for the updating of seasonal annual IIVs.<sup>21</sup> Clinical trials are no longer required for lineage changes of licensed IIVs.<sup>22</sup> Inactivated vaccines have an excellent safety profile, and are recommended for children of  $\geq 6$  months of age, the elderly, asthmatics and those individuals with other high-risk conditions.

## Trivalent Influenza Vaccines

Trivalent influenza vaccines (TIVs) (containing A/H1N1, A/H3N2 and one B lineage) have been manufactured since 1978, replacing the bivalent inactivated influenza vaccines that had been widely used since 1944 (Table 1).<sup>23</sup>

During the 1990–2006 and 2008–2009 influenza seasons, Muhammad et al.<sup>24</sup> investigated possible new or unexpected AEs following TIV administration to children aged 2 to 17 years and 5 to 17 years, respectively. From 1990 to 2006, 2,054 cases of vaccine AEs were reported, peaking in the 2003–2004 influenza season, whereas 506 were reported in 2008–2009. Higher proportions of medication errors and Guillain-Barré Syndrome (GBS) were observed, although the latter could not be causally correlated with vaccination. Among 201 reports regarding medication errors, 94% did not cause AEs other than the medication error itself.

TIV vaccination is recommended for children older than 6 months and between 6 and 59 months with a predisposition to severe influenza in Australia and Western Australia, respectively.<sup>25</sup> In 2010 in Australia, an increase in febrile convulsions (FCs) was observed after TIV immunization; however, this involved only one brand, produced by bioCSL (Fluvax and Fluvax Junior). Subsequently, Li-Kim-Moy and coll.<sup>26</sup> reviewed the safety of TIV administration. Specifically, they investigated the rates of fever, FCs and serious AEs reported in both unpublished and published clinical trials conducted on children during the period 2005–2012. The incidence of fever or AEs caused by TIV was low, whereas higher fever rates were correlated with bioCSL influenza vaccines in young children. However, it was not possible to attribute this to the TIV strain composition. This study highlights the necessity to strictly monitor seasonal influenza vaccine safety and to report post-administration data accurately.<sup>26</sup> A recent study conducted by Esposito et al.<sup>27</sup> investigated the tolerability and safety of TIV in overweight and obese children between 3 and 14 years old, since obesity is an important risk factor for infections that are facilitated by respiratory diseases. In overweight/obese children, the antibody response upon TIV vaccination was similar to or slightly greater than that observed in normal-weight subjects of similar age, and this situation persisted for at least 4 months after vaccine administration. The incidence of local and systemic reactions was comparable between the groups,

**Table 1.** Vaccine types and route of administration.

Vaccine types	Route of administration
TIV	Parenteral Intradermal
QIV	Parenteral
LAIV	Intranasally

and no serious AE was observed, confirming that influenza vaccines have a good safety profile even in overweight/obese children.<sup>27</sup>

### Quadrivalent Influenza Vaccines

In addition to the 3 strains present in TIV, namely H1N1 and H3N2 influenza A subtypes and influenza B, the formulation of Quadrivalent Influenza Vaccines (QIVs) contains two additional influenza B lineages, Yamagata and Victoria, which have been spreading since 1985 and have reduced the efficacy of TIV.<sup>28</sup> QIVs should enhance protection against influenza B by avoiding the possibility of a B strain mismatch. The first quadrivalent LAIV was licensed in 2012 and, after several QIV formulations had been tested, it entered the market (Table 1).<sup>29</sup>

The WHO recommended both B lineages for inclusion in the 2012–2013 influenza seasonal vaccine in the Northern hemisphere. In the US, 4 QIVs have recently been approved: the three inactivated vaccines *Fluarix*<sup>TM</sup>, *FluLaval*<sup>TM</sup> (both GlaxoSmithKline Vaccines) and *Fluzone*<sup>®</sup> (Sanofi Pasteur) and the LAIV *FluMist*<sup>®</sup> (MedImmune).<sup>30</sup> In a phase-II multi-center study conducted on healthy adults aged  $\geq 18$  years, Greenberg et al.<sup>31</sup> compared the safety and immunogenicity of a QIV whose formulation contained two influenza B strains versus licensed TIVs containing either a Victoria B-lineage strain (2009–2010 TIV) or a Yamagata B-lineage strain (2008–2009 TIV). Seroprotection, seroconversion and AEs were comparable in all groups.

Pépin and coll.<sup>32</sup> investigated the immunogenicity and safety of a prototype inactivated QIV immunization (containing A/California/07/2009 (H1N1), A/Victoria/210/2009 (H3N2), B/Brisbane/60/2008 (Victoria lineage) and B/Florida/04/2006 (Yamagata lineage) strains) in comparison with both a licensed 2011–2012 TIV (containing A/California/07/2009 (H1N1), A/Victoria/210/2009 (H3N2) and B/Brisbane/60/2008 (Victoria lineage) strains) and an investigational TIV (containing the alternative B strain lineage B/Florida/04/2006 (Yamagata lineage), the A/California/07/2009 (H1N1) and A/Victoria/210/2009 (H3N2) strains). They conducted a phase-III, randomized, active-controlled, multi-center trial involving 1568 adults during the 2011/2012 influenza season. All groups had similar pre-vaccination HAI antibody titers and showed an increase following immunization. Antibody responses following QIV administration were not inferior to those elicited by the TIVs for all the matched strains. Moreover, the QIV was able to induce higher antibody responses against the B strains not contained in the TIVs. All the strains contained in the QIV met the EMA criteria for both age-groups of subjects (18–60 years and  $> 60$  years). With regard to the TIVs, however, only the A and matched B strains met all EMA criteria; the unmatched B strains did not. The fact that all three vaccines evoked higher responses and response rates in the younger adults than in the elderly adults is in agreement with the literature, and is due to the waning responsiveness of the elderly immune system and to other aging-factors.<sup>33,34</sup> A meta-regression study conducted by Beyer and coll.<sup>35</sup> further confirmed that the benefit of QIV depends on age. Indeed, they observed that the impact of B lineage mismatch was negatively associated with pre-seasonal immunity. Infants and children benefited most from QIV since they had not yet been exposed to influenza B; accordingly, vaccine effectiveness declined as pre-seasonal

immunity increased. QIV administration may therefore provide less significant protection in the elderly than in the young in the case of lineage mismatch.

The safety and reactogenicity of QIV have proved similar to those of seasonal influenza vaccines, as demonstrated by Tinoco et al.<sup>36</sup> The most common adverse reactions were pain at the injection site, headache and myalgia, all of which disappeared within 3 days of vaccination. No serious AE or death were registered.

Similar results regarding the safety of the first QIV introduced in Australia were reported by Regan et al.<sup>37</sup> in a sample of 1,685 healthcare providers (HCPs). Although 7 days after immunization no AE was observed in either QIV- or TIV-vaccinated subjects, a slightly but significantly higher percentage of QIV-immunized than TIV-immunized HCPs reported pain or swelling at the injection site. That study confirmed the safety of QIV, since its reactogenicity was similar to that of TIV. The meta-analysis recently conducted by Moa and coll.<sup>38</sup> also showed no significant differences between the safety profiles of QIV and TIV, except for a slightly higher rate of injection-site pain following QIV immunization, which may have been due to the higher dose (60 versus 45 mcg), in agreement with the results of the study by Regan.<sup>37</sup>

It has been suggested that differences in production methods yielding vaccines of different composition – in addition to the presence of a further antigen in QIV – may be responsible for the different frequency of AEs.<sup>37</sup> However, although QIV elicited slightly more local reactions (injection-site pain) than TIV, the potential benefit of QIV in protecting the population from infection is considered to be greater.<sup>38</sup>

The safety and reactogenicity profile of inactivated QIV in children aged 18–47 months was evaluated by Rodriguez Weber and coll.<sup>39</sup> in a phase-II double-blind study. Reactogenicity was investigated since QIV contains 60  $\mu\text{g}$  of antigen compared with 45  $\mu\text{g}$  in TIV. Serious AEs were monitored for 6 months after immunization. The reactogenicity and safety profiles of QIV were similar to those observed for TIV.

An investigation on the VAERS reports following vaccination with IIV4 and trivalent IIV3 from 7/1/2013 to 5/31/2015 was conducted by Haber et al.,<sup>40</sup> who reported similar safety profiles between the two vaccines. This observation was in agreement with the data obtained from pre-licensure studies of IIV4. Most of the AEs reported were non-serious. Among the most frequent AEs in persons aged between 6 months and 17 years, were fever, injection-site swelling and erythema, whereas pain in the extremities and injection-site pain were most frequent in individuals aged 18–64 years. The most common non-lethal serious events were GBS, seizures, injection-site reactions and anaphylaxis.

### Live attenuated influenza vaccines

LAIVs have been used in Russia for decades, and were licensed in the US in 2003 for healthy subjects aged 2–49 years<sup>41</sup> and in Europe in 2012 for healthy children aged 2–17 years. They are able to induce a stronger immune response than IIV by mimicking natural infection (see below).<sup>20</sup> Since they are administered intranasally, several adaptive immune responses, such as serum antibodies, mucosal and cell-mediated immunity are

induced.<sup>42</sup> The evoked immune response directed towards neuraminidase and hemagglutinin glycoproteins is similar to that elicited by the process of naturally occurring infection.<sup>43,44</sup> The fact that a higher incidence of infections involving the lower airways was not observed supports the notion that the virus is unable to replicate and induce pathology in the respiratory tract.<sup>45,46</sup> Consequently, protection against the virus contained in the vaccine formulation and mismatched strains is induced by LAIVs.<sup>47</sup> The development of severe influenza following LAIV immunization is prevented, since the vaccine contains a cold-adapted influenza virus that is unable to replicate in temperature conditions  $>37.8^{\circ}\text{C}$ .<sup>43,44</sup> LAIV is not recommended in elderly or immunosuppressed subjects or in those who are caring for persons in whom severe influenza disease carries high risk. LAIVs are not recommended for children  $< 2$  years of age, as, in early investigations, the administration of LAIVs to this age-group promoted the onset of wheezing. Furthermore, LAIVs are contraindicated in severe asthmatics currently on oral or high-dose inhaled glucocorticosteroids or who have active wheezing.<sup>47,48</sup>

Concomitant immunization with other usual childhood vaccines has been shown not to influence the immune response induced by LAIV in healthy young children.<sup>49</sup>

Furthermore, LAIVs proved to be more effective than TIV in reducing the incidence of influenza illness in two open-label studies conducted on children aged 6–71 months affected by recurrent respiratory tract illnesses and in children and adolescents with asthma aged 6–17 years.<sup>49</sup> LAIV displays a good safety profile, comparable to that of TIV.<sup>46,50–53</sup>

LAIV vaccinees show the presence of the vaccine virus, but the risk of transmitting the virus to household members is marginal, ranging from 0.58% to 2.87%. In only one case has the transmission of LAIV virus to a placebo recipient been reported. In that case, however, transmission did not induce the disease.<sup>54</sup> It has been observed that, in children aged 9–36 months, the presence of the virus is highest 3–5 days after vaccination, reaching up to 80%, whereas it is lower in adults affected by HIV (1.8%).<sup>55</sup> Furthermore, not only do LAIVs elicit direct protection in vaccinated subjects, they also promote indirect protection by reducing the transmission of the influenza virus among subjects belonging to clinical risk groups.<sup>56</sup> LAIVs have been reported to cause adverse effects in 15% of cases. However, these are not serious: nasal congestion, runny nose and slight fever in adolescents, and sore throat in adults. With the exception of fever, which has been reported on the day after vaccination, the other symptoms occur 2–3 or 8–9 days after LAIV administration.<sup>45</sup> LAIVs have been reported to cause slightly more troublesome moderate adverse effects than TIV, though the incidence of these is low. The difference was significantly higher following the first dose, but disappeared after the second administration<sup>48</sup> and was reduced following the subsequent annual vaccinations. Although one of the most frequent side effects in young children was wheezing, no difference in severity, length of hospitalization or treatment was observed.<sup>45,48</sup> Furthermore, asthma episodes occurring in LAIV vaccinees showed a 4-fold increase in comparison with controls in the 42 days after vaccination.<sup>45</sup>

Severe consequences have rarely been reported, and have displayed a similar frequency after LAIV, TIV and placebo; no

association with vaccine administration has been proved. Recently, McNaughton's group investigated the incidence of adverse effects of interest (AEIs) in children and adolescents upon immunization with nasal QLAIV (Fluenz Tetra, Astra Zeneca) in the same influenza season in England. They reported nasal congestion, cough and malaise among the most frequent AEIs. No serious AE, hospitalization or death was reported during the investigation.<sup>57</sup>

Since a higher frequency of fever has been reported after LAIV than after IIV vaccine administration, a recent prospective observational study conducted by Stockwell's group<sup>58</sup> investigated the frequency of fever following immunization of young children with IIV in 3 community clinics in New York City. A low frequency of fever was found and no difference between the vaccines evaluated was observed during the 2013–2014 influenza season.<sup>58</sup>

The studies conducted by Carr et al.<sup>59</sup> and King et al.<sup>60</sup> confirmed the safety of LAIV in children affected by cancer and in HIV-infected adults, respectively.

However, discordant data on the efficacy of LAIV have emerged between the US and Europe.<sup>61</sup> Specifically, owing to ineffectiveness during the previous three seasons (2013–2014, 2014–2015 and 2015–2016),<sup>62</sup> the use of LAIV was not recommended in the US during the 2016–2017 influenza season, and the recommendation not to use LAIV has been renewed for the 2017–2018 flu season.<sup>63</sup> Conversely, many other health authorities, including those in the UK and Canada, consider the efficacy of LAIVs to be adequate. Several factors have been hypothesized to have played a role in the diminished vaccine effectiveness, including methodological issues in the studies.<sup>64</sup>

### **LAIV in egg-allergic individuals, asthmatic subjects or children with recurrent wheezing**

Until recently, few safety data regarding LAIV administration in egg-allergic young children were available, although egg allergy is relatively common, affecting between 2–6% of pre-school children.<sup>65</sup>

In the US, the prevalence of asthma<sup>66,67</sup> and egg allergy<sup>68</sup> has prompted vaccine manufacturers to tackle the problem of immunizing egg-allergic patients in whom vaccination with egg-containing influenza vaccine is recommended.

In the 1970s, egg-allergic patients had to undergo skin testing with the influenza vaccine<sup>69–71</sup>; if the result was negative, they could be safely immunized, otherwise vaccination was not recommended. However, a subsequent study conducted by Murphy and Strunk<sup>72</sup> found that influenza vaccination was safe even in the event of a positive skin-test result if a protocol of multiple, graded injections was implemented, whereas Zeiger<sup>73</sup> suggested that influenza vaccine skin tests (prick and intradermal) should be carried out before vaccine administration in individuals with a history of adverse reactions to eggs and positive skin-test results. A single dose could be administered if the influenza vaccine skin-test results were negative, while a 2-dose graded or desensitization protocol should be implemented if they were positive.<sup>73,74</sup> The safety of administering the influenza vaccine in a graded 2-dose fashion to egg-allergic children without performing the vaccine skin test was investigated by

Chung and coll.<sup>75</sup> in a retrospective chart-review study, which suggested that the skin test could safely be omitted.

A recent investigation conducted by Turner et al.<sup>65</sup> found a low risk of systemic allergic reactions following LAIV immunization in subjects aged 2–18 years during the influenza season 2014–2015 in the UK; 35% of the children had a history of anaphylaxis to eggs. Immediate AEs following LAIV immunization were mild and self-limiting; these were: contact/localized urticaria, rhinitis and oropharyngeal itching. Delayed adverse effects potentially correlated with LAIV were lower respiratory tract symptoms, which occurred within 72 hours of vaccination. This higher incidence was reported in young children, but it did not reach statistical significance. Delayed events were not associated to any risk factor. In addition, the vaccine was well tolerated by asthmatic subjects and those under 5 years of age who were affected by recurrent wheezing<sup>65</sup>; this finding is in agreement with those of other studies.<sup>46,48,50,76–78</sup> However, certain guidelines in North America do not currently recommend its use in subjects of this age who have had an episode of wheezing in the previous year.<sup>79</sup>

### **Pandemic influenza vaccines**

Any pandemic influenza vaccine may have an incompletely described safety profile.<sup>80</sup> A correlation between influenza vaccines and GBS has been reported by several studies – in 1976<sup>81</sup> and in 1992–1994<sup>81–83</sup> – and by three meta-analyses.<sup>84–86</sup> The authors of these last studies reported a 2–3-fold higher risk of GBS in subjects vaccinated with either adjuvanted or non-adjuvanted A(H1N1)pdm09 vaccines in comparison with unvaccinated subjects. However, contrasting results have also been reported.<sup>87–90</sup> The potential adverse effect of A(H1N1)pdm09 monovalent or trivalent vaccination was also assessed by Alcalde-Cabero and coll.,<sup>91</sup> but no association was found.

Recent epidemiological investigations have confirmed the association between an AS03-adjuvanted pandemic influenza vaccine (Pandemrix, GlaxoSmithKline Biologicals, Germany) and the onset of narcolepsy in children and adolescents.<sup>92</sup> The novel circulating A(H1N1) influenza virus was identified in April 2009 and quickly spread worldwide in June 2009. Millions of A(H1N1) pandemic vaccine doses were produced within a narrow time-window (from April 2009 until November of the same year). One year after the European AS03-adjuvanted A(H1N1) pandemic vaccine was authorized in Europe, a higher number of narcolepsy cases was observed in Sweden and Finland (9.0/100,000 incidence in vaccinees versus 0.7 in unvaccinated subjects),<sup>92–95</sup> and also in other countries.<sup>11,96</sup> It was hypothesized that a peptide located on a surface-exposed region of influenza nucleoprotein A was characterized by protein residues similar to the first extracellular domain of hypocretin (HCRT) receptor 2. In accordance with this hypothesis, a higher frequency of antibodies to HCRT receptor 2 was found in sera from narcoleptic Finnish patients immunized with the European AS03-adjuvanted vaccine Pandemrix<sup>92</sup> than in unvaccinated subjects. Furthermore, a cross-reaction between HCRT receptor 2 and influenza nucleoprotein was described. No persistent antibody response to nucleoprotein was detected in sera from non-narcoleptic subjects vaccinated with Focetria (a vaccine differently produced), which contained 72.7% less

influenza nucleoprotein. Thus, differences in vaccine nucleoprotein content and the respective immune response could explain the correlation between narcolepsy and Pandemrix.<sup>97</sup>

A recent study<sup>98</sup> investigated the annual frequency of anaphylaxis following immunization, a rare AE which can be life-threatening and causes hospitalization within 48 hours after immunization. The study was conducted on subjects younger than 18 years in Germany between June 2008 and May 2010. Of the 22 cases of anaphylaxis evaluated, 8 were due to the administration of AS03-adjuvanted A/H1N1 pandemic influenza vaccine. This vaccine was associated with a higher risk of anaphylaxis than other vaccines, with an incidence of 11.8 of cases per 1,000,000 doses administered.

### **Age-groups**

While influenza viruses infect all age-groups, children and adults over the age of 65 years are most at risk. Vaccination is recommended for these age-groups, for pregnant women, for subjects with high-risk conditions due to complications of influenza and for those with chronic medical conditions (metabolic, cardiac, pulmonary or kidney diseases, and immunocompromised patients). The same recommendation is generally extended to nurses and healthcare workers.<sup>99,100</sup>

Most influenza vaccines are safe in adults and children. However, they can sometimes cause AEs. According to the age-group, AEs may include fever, vomiting, nausea, headache, irritability, injection site reaction and rash.<sup>9,100</sup>

### **Children**

Infants and children (particularly those younger than 5 years old) are especially susceptible to influenza infection and its complications, such as pneumonia. These subjects play a primary role in the transmission of influenza viruses, since they acquire and release greater amounts of virus than adults.<sup>101–103</sup>

In 2003 in the US, influenza vaccination was officially recommended for healthy children aged 6–23 months, and in 2008 “universal” vaccination of all subjects over 6 months of age was recommended.<sup>102,104</sup>

The scenario is different in Europe, where, despite several recommendations by international experts and advisory groups, pediatric vaccination has not reached a satisfactory level.<sup>105</sup>

Worldwide, TIVs are currently the only injectable preparations authorized for pediatric use in children above 6 months of age.<sup>101</sup>

Several studies have evaluated the safety of TIVs in healthy children, and have found a good safety profile with no serious AEs.<sup>106–109</sup> The most common solicited local reactions are pain and redness at the injection site, while the most common solicited systemic reaction is irritability, followed by malaise and headache (Table 2).<sup>107–110</sup>

In the USA, the recommended dose for children below 3 years of age is half of the adult dose. However, several studies have provided evidence that the administration of a full dose is safe in children and does not increase reactogenicity.<sup>107,108,110</sup> More specifically, local reactions are more common in toddlers than in infants, and in full-dose vaccinees, though the differences are not significant.<sup>108</sup> As stated above, the most commonly

**Table 2.** Most common local and systemic reactions in children.

Children		
Vaccine	Local reaction	Systemic Reaction
TIV	Pain Redness Tenderness	Irritability Malaise Headache
adjuvanted TIV	Pain Tenderness Erythema Induration	Irritability Diarrhea Crying Fatigue Chills Headache Fever Myalgia
LAIV	Nasal congestion	Fever Decreased activity
Pandemic	Pain Redness Swelling	Malaise Fatigue Myalgia

reported systemic reaction is irritability, whereas the most common local reactions are redness and tenderness in the first 3 days after vaccination.<sup>107,108</sup> Concerning other local reactions, swelling and induration more frequently occur after a full dose, but are less commonly reported.<sup>108</sup>

In addition, cell-derived influenza vaccines are also well-tolerated and have a good safety profile – comparable to that of egg-derived influenza vaccines – in children.<sup>111,112</sup> Pain at the injection site is the most common local reaction, while the most commonly reported systemic reactions are: malaise in the 4-8-year-old cohort and headache among 9-17-year-olds (Table 1).<sup>112</sup>

Esposito et al.<sup>113</sup> evaluated the safety and reactogenicity of intradermal (ID) influenza vaccine, an alternative route of injection to the traditional intramuscular (IM) modality, in children older than 3 years. Although local reactions were more common in the cohort of ID vaccinees than in the IM vaccine group, they were transitory and did not become more frequent as the vaccine dose increased.

However, the efficacy of TIVs is not completely satisfactory in children. For this reason, adjuvanted vaccines have been developed in order to improve the immune response. Clinical studies have demonstrated the great advantage of these vaccines, which are able to induce an enhanced immune response in children, even against B strains, in the case of low pre-immunization titers and mismatching viruses.<sup>1</sup> Overall, adjuvanted vaccines induce slightly higher local and systemic reactogenicity than TIVs; however, the reactions are mild and transient, and there is no increase in unsolicited AEs.<sup>114-118</sup> In children younger than 36 months, the most commonly reported local reactions are injection-site pain, tenderness and erythema (Table 2),<sup>114,115,117</sup> while the most common systemic reactions are irritability, diarrhea and crying (Table 2).<sup>114,117</sup> In older children injection-site pain, erythema and induration are the most common local reactions, while systemic reactions are: fatigue, chills, headache, fever and myalgia (Table 2).<sup>114,116,117</sup> Fever displays a higher incidence after the second dose.<sup>116</sup> Overall, children older than 36 months display a higher incidence of solicited reactions than younger children.<sup>114</sup>

Recently, seasonal inactivated QIV containing both the Victoria and Yamagata lineages of the B virus have been marketed; these have shown a superior antibody response against the additional B strain and immunogenicity comparable to the traditional TIVs.<sup>1,119</sup> In children aged 6–35 months, their safety profile is acceptable and similar to that of TIVs, and their reactogenicity seems not to be excessive on increasing the amount of influenza antigen.<sup>120,121</sup>

The other licensed vaccine is the LAIV, which is administered intranasally to persons aged 2–49 years in the USA, Europe, India and Russia. The advantages of the LAIV vaccine are its ability to mimic the natural pathway of infection, to induce a broader humoral and cellular response than TIV and to provide protection against both well-matched and antigenically drifted strains.<sup>1</sup> The most frequently reported reaction is nasal congestion<sup>57,122</sup> together with low-grade fever and decreased activity (Table 2).<sup>122</sup> These symptoms did not occur after the second dose.<sup>122</sup> While no serious AE has been reported,<sup>122-124</sup> McNaughton et al.<sup>57</sup> reported asthma in a large number of study participants, which suggests that quadrivalent LAIV should not be administered to children or adolescents with severe asthma or active wheezing.

Vaccination remains the most effective strategy for preparing for seasonal infections and for a possible pandemic. The WHO guidelines state that, whenever possible, the safety of pandemic vaccines should be evaluated before the pandemic. However, the safety profile of a pandemic influenza vaccine may not be completely investigated.<sup>80,125</sup>

Most of the pandemic vaccines against the H1N1 pdm09 influenza virus have been evaluated. Overall, they have shown a clinically acceptable safety profile, without any serious AEs or potentially immune-mediated diseases.<sup>126-128</sup> As for the other vaccines, the most commonly reported local reaction is injection-site pain, together with redness and swelling (Table 2).<sup>127-131</sup> The most frequent systemic reactions are malaise, fatigue and myalgia (Table 2).<sup>127,132</sup> Plennevaux et al.<sup>131</sup> reported that headache, myalgia and malaise were more common in children older than 24 months, while irritability, abnormal crying, loss of appetite and drowsiness occurred more frequently in children younger than 24 months. The most common unsolicited AEs are upper respiratory tract infection<sup>126,127</sup> and nasopharyngitis.<sup>127</sup> Adjuvanted and non-adjuvanted H5N1 vaccines are safe and well tolerated, though Diez-Domingo et al.<sup>133</sup> reported one potential immune-mediated disease (autoimmune hepatitis) related to vaccination.

## Adults and the elderly

Influenza vaccination is generally recommended for the elderly, as they are at risk of, and more vulnerable to, influenza complications.<sup>134</sup> The European guidelines do not include other groups among those recommended for vaccination, though vaccination has been strongly suggested for caregivers and healthcare workers.<sup>135</sup> However, influenza disease in adults carries a significant societal cost in terms of absence from work and lost productivity.<sup>136,137</sup>

Several studies have evaluated the safety profile of egg/cell-derived, adjuvanted/non-adjuvanted influenza TIV and QIV in adults and elderly subjects. Overall, the vaccines showed a

robust safety profile and acceptable reactogenicity. Injection-site pain is the most frequently reported local symptom (Table 3).<sup>31,136,138-143</sup> The most frequent systemic reactions in both adults and the elderly are fatigue, headache and myalgia (Table 3).<sup>31,136,140-146</sup> Only one study reported fever as the most common solicited reaction.<sup>139</sup> Rates of solicited local and systemic reactions are higher in adults than in the elderly<sup>31,139,141,142,145,147,148</sup> and in females than in males.<sup>145</sup> Unsolicited AEs are nasopharyngitis and cough.<sup>31,136,138,146</sup> Overall, no serious AEs or deaths related to influenza vaccination are reported<sup>31,142,143,145,146,149</sup> with the exception of two studies. The first of these<sup>136</sup> described serious AEs in the QIV group (myocardial infarction and cerebrovascular accident) and the TIV group (pneumonia, cerebrovascular accident, nephrolithiasis and arteriosclerosis). The second<sup>138</sup> reported one death, possibly related to vaccination, and SAEs (bronchitis, asthmatic crisis, chronic obstructive pulmonary disease and GBS) possibly or probably related to vaccination with TIV, with and without adjuvant.

The ID vaccines are well tolerated in adults and the elderly and have not raised safety concerns.<sup>137,150</sup> Malaise and headache are reported to be the most frequent systemic reactions<sup>137,151</sup> and their profile is similar to that of vaccines injected via the IM route.<sup>152,153</sup> Local reactogenicity is reported to be higher after ID vaccination than after IM vaccination<sup>137,152,153</sup> even when subjects are re-vaccinated with ID vaccine.<sup>137</sup> Swelling appears to be more common in the case of ID vaccination in the previous year.<sup>137</sup>

LAIV, whether trivalent or quadrivalent, is safe, without any increased risk after administration.<sup>124,154</sup> The vaccine is currently approved in the USA, Europe, India and Russia for subjects aged 2–49 years. However, it has also been evaluated in adults and the elderly.<sup>155,156</sup> Reactions after LAIV vaccination include cough, sore throat, runny nose/nasal congestion and decreased appetite.<sup>155,156</sup> No significant AEs following LAIV vaccination have been reported<sup>51</sup> with the exception of upper and lower respiratory tract infections, wheezing, rhinitis and sneezing.<sup>124,156,157</sup>

With regard to children, most of the pandemic vaccines, with or without adjuvant, are against the pandemic H1N1 influenza virus.<sup>158-164</sup> However, pre-pandemic vaccines, such as those against H5N1, H7N9 and H5N1, including LAIV,

have also been evaluated.<sup>165-167</sup> Overall, these vaccines have displayed good tolerability and satisfactory safety profiles.<sup>158,160,162-164</sup> The most common local reaction is injection-site pain, while systemic events are fever, headache, malaise, myalgia and fatigue.<sup>111,158-161,163,164</sup> After the second dose, both types of reaction are similar to those seen after the first, or are attenuated.<sup>111,161,164</sup>

### High-risk individuals

Individuals of any age with certain medical conditions are at increased risk of influenza-related complications than the general population. Vaccination remains the most effective method of controlling and preventing influenza infections, and health authorities have included individuals with chronic medical conditions among those recommended for influenza vaccination.<sup>168</sup> The only authorized vaccine for this target group is TIV, as the safety of LAIV has not been established.<sup>169</sup> However, despite the recommendation, vaccination coverage remains low among high-risk individuals.<sup>170</sup>

Several studies have evaluated the safety profile of seasonal and pandemic influenza vaccines in high-risk individuals and have shown that vaccines are well tolerated and safe in this target group.<sup>27,152,171-176</sup> However, the conventional vaccines are reported to induce a poor immune response in high-risk individuals, and different strategies, such as administration of a high-dose booster, the use of adjuvants and ID administration, have been evaluated.<sup>173</sup>

Standard doses, high doses and booster doses of TIV have proved safe and well tolerated in high-risk adults, such as hematopoietic stem cell transplantation patients, individuals with type 2 diabetes, solid transplant recipients, patients with multiple myeloma and with Duchenne muscular dystrophy; no unexpected serious AEs have been recorded.<sup>171-173,177,178</sup> Specifically, the most common local reaction is pain at the injection site, while the most frequently reported systemic reactions are myalgia and general malaise (Table 4). No significant differences in local and systemic reactions between high-risk individuals and control groups have been reported.<sup>171,177</sup> Two studies, however, detected a trend towards a lower incidence of local and systemic reactions in patients with type 2 diabetes after seasonal vaccination and in those with Duchenne muscular dystrophy after pandemic vaccination.<sup>173,179</sup> There are no safety concerns regarding the administration of ID vaccines in high-risk individuals, such as HIV-infected adults and immunocompromised patients. However, local and systemic reactions are higher with ID than IM formulations.<sup>152,172</sup>

The safety of seasonal and pandemic influenza vaccines in children with underlying medical conditions has been proven,

**Table 3.** Most common local and systemic reactions in adults and the elderly.

Vaccine	Adult - Elderly	
	Local reaction	Systemic Reaction
TIV/QIV	Pain	Fatigue
adjuvanted-non adjuvanted		Myalgia Headache
LAIV	Cough Sore throat Runny nose/nasal congestion	Decreased appetite
Pandemic	Pain	Fever Headache Malaise Fatigue Myalgia

**Table 4.** Most common local and systemic reactions in high-risk individuals.

Vaccine	High-risk individuals	
	Local reaction	Systemic Reaction
TIV	Pain	Myalgia Myalgia
Pandemic	Pain Tenderness	Fatigue Decreased activity

and no severe AEs have been reported.<sup>27,113,174-176,180,181</sup> The most common local reactions are pain<sup>174,180</sup> and tenderness, while systemic reactions consisting of fatigue and decreased general activity have been noted (Table 4).<sup>180</sup> Studies have revealed that standard-dose TIV in overweight and obese children and high-dose TIV in children and young adults with cancer induce more solicited reactogenicity events, though the difference is not statistically significant.<sup>27,175</sup>

## Conclusions

Influenza is still a substantial cause of death and suffering during the winter months, and imposed a heavy socioeconomic burden, especially in young subjects and the elderly.<sup>134</sup> Although vaccination remains the single best defense against influenza and its complications, in many European countries, vaccination coverage is suboptimal, especially in comparison with the US. This has serious consequences, such as the evident excess mortality registered in Italy in elderly subjects who were not vaccinated against influenza in 2015.<sup>182</sup> These data, which should be confirmed by further investigations, highlight the necessity to increase rates of immunization through the planning and implementation of public health interventions. Furthermore, a higher standardization of vaccine strategies has been observed in the US than in European countries.<sup>183</sup> Although influenza vaccines display a good safety profile, a growing number of people shun vaccination for fear of negative side effects,<sup>92</sup> such as the onset of autoimmune conditions. This fear, in addition to the public's misperceptions concerning adjuvants and their role, have discouraged vaccination not only against influenza but also against other infectious diseases, allowing them to re-emerge.<sup>92</sup> A significant element in the overall effectiveness of vaccines is therefore their acceptance by the public.<sup>184</sup>

However, not only infective agents are associated with increased morbidity and mortality, as has previously been described; it has also been hypothesized that an impaired or inappropriate modulation of Toll-like receptors (TLRs), which are involved in the recognition of invading microorganisms, and in the defense of the host following natural infections, could exert a critical role in the development of autoimmune conditions.<sup>185</sup>

Overall, influenza vaccines are very safe<sup>186</sup> and well tolerated in most age-groups and formulations. Admittedly, they can cause AEs and/or rare AEs, some of which are more prevalent in children, while others are more prevalent in adults. However, symptoms due to AEs, such as rhinorrhea or congested nose, are usually transient. Severe allergic reactions to influenza vaccines are very rare, being estimated at less than 1 in a million doses.<sup>187</sup>

Another critical factor is that the currently available influenza vaccines are not well suited for use in low and middle-income countries (LMIC),<sup>188</sup> the health systems of which often lack the resources to implement vaccination adequately. Indeed, the WHO standards concerning the programmatic suitability of vaccines are not met by many influenza vaccines in LMICs. In these conditions, the priority target group is that of young children (< 5 years), whereas other risk groups are considered secondary targets.<sup>189</sup>

Further studies of all influenza vaccines, involving follow-up periods to bring to light possible increases in hospitalization,

should be conducted on children < 2 years, children from LMICs or children with prior asthma or wheezing. It is necessary that safety tests be conducted in this age group, for which data regarding AEs upon LAIV administration are currently insufficient.

Vaccines have to meet higher safety standards, since they are administered to healthy people, mainly healthy children.<sup>8</sup> The monitoring of annual influenza vaccine safety, which is particularly important on account of the annual changes in the viral antigen composition of the vaccine, constitutes a critical component of the influenza vaccination program. Indeed, not only does this strategy ensure the safety of vaccines, it can also maintain public trust in the national vaccination program. However, it must be borne in mind that no vaccine is 100% safe in all subjects, that vaccines may potentially cause AEs, and that the safety profile of a given pandemic influenza vaccine may not be completely described.<sup>3,80</sup>

## Disclosure of potential conflicts of interest

No potential conflicts of interest were disclosed.

## References

1. Trombetta CM, Montomoli E. Influenza immunology evaluation and correlates of protection: a focus on vaccines. *Expert Rev Vaccines*. 2016;15(8):967-76. doi:10.1586/14760584.2016.1164046.
2. Grohskopf LA, Sokolow LZ, Olsen SJ, Bresee JS, Broder KR, Karron RA. Prevention and control of influenza with vaccines: recommendations of the advisory committee on immunization practices, United States, 2015-16. *Influenza Season. Morb Mortal Wkly Rep (MMWR)*. 2005;64(30):818-825. CDC.
3. Global Advisory Committee on Vaccine, S. and W.H.O. secretariat, Global safety of vaccines: strengthening systems for monitoring, management and the role of GACVS. *Expert Rev Vaccines*. 2009;8(6):705-16. doi:10.1586/erv.09.40.
4. Halsey NA. The science of evaluation of adverse events associated with vaccination. *Semin Pediatr Infect Dis*. 2002;13(3):205-14. doi:10.1053/spid.2002.125864.
5. WHO. Casualty assessment of an adverse event following immunization (AEFI). 2013;1-56. ISBN: 978 92 4 150533 8.
6. CDC. Understanding the vaccine adverse event reporting system (VAERS). 2013.
7. FDA, Guideline for Industry. Clinical safety data management: definitions and standards of expedited reporting. ICH-E2A. 1995;1-17.
8. McPhillips H, Marcuse EK. Vaccine safety. *Curr Probl Pediatr*. 2001;31(4):91-121.
9. Halsey NA, Talaat KR, Greenbaum A, Mensah E, Dudley MZ, Proveaux T, Salmon DA. The safety of influenza vaccines in children: An Institute for Vaccine Safety white paper. *Vaccine*. 2015;33(Suppl 5):F1-F67. doi:10.1016/j.vaccine.2015.10.080.
10. Li R, Stewart B, McNeil MM, Duffy J, Nelson J, Kawai AT, Baxter R, Belongia EA, Weintraub E. Post licensure surveillance of influenza vaccines in the Vaccine Safety Datalink in the 2013-2014 and 2014-2015 seasons. *Pharmacoepidemiol Drug Saf*. 2016;25(8):928-34. doi:10.1002/pds.3996.
11. ECDC. Enhanced monitoring of vaccine safety for 2009 pandemic vaccines. 2013.
12. Hanley JA, Lippman-Hand A, If nothing goes wrong, is everything all right? Interpreting zero numerators. *JAMA*. 1983;249(13):1743-5. doi:10.1001/jama.1983.03330370053031.
13. Sarkanen TO, Alakuijala APE, Dauvilliers YA, Partinen MM. Incidence of narcolepsy after H1N1 influenza and vaccinations: Systematic review and meta-analysis. *Sleep Med Rev*. 2017. pii: S1087-0792 (17)30001-1. doi:10.1016/j.smrv.2017.06.006. [Epub ahead of print]



14. European Medicine Agency (EMA). Guideline on influenza vaccines. Non-clinical and clinical module. EMA/CHMP/VWP/457259/2014. 2016.
15. Bricout H, Chabanon AL, Souverain A, Sadorge C, Vesikari T, Caroe TD. Passive enhanced safety surveillance for Vaxigrip and Intanza 15 microg in the United Kingdom and Finland during the northern hemisphere influenza season 2015/16. *Euro Surveill*. 2017;22(18):1–9. doi:10.2807/1560-7917.ES.2017.22.18.30527.
16. Moro PL, Li R, Haber P, Weintraub E, Cano M. Surveillance systems and methods for monitoring the post-marketing safety of influenza vaccines at the Centers for Disease Control and Prevention. *Expert Opin Drug Saf*. 2016;15(9):1175–83. doi:10.1080/14740338.2016.1194823.
17. Wijnans L, Voordouw B. A review of the changes to the licensing of influenza vaccines in Europe. *Influenza Other Respir Viruses*. 2016;10(1):2–8. doi:10.1111/irv.12351.
18. Huang YL, Moon J, Segal JB. A comparison of active adverse event surveillance systems worldwide. *Drug Saf*. 2014;37(8):581–96. doi:10.1007/s40264-014-0194-3.
19. Giancchetti E, Trombetta CM, Piccirella S, Montomoli E. Evaluating influenza vaccines: progress and perspectives. *Future Virology*. 2016;11(5):379–93. doi:10.2217/fvl-2016-0012.
20. Sridhar S, Brokstad KA, Cox RJ. *Influenza Vaccination Strategies: Comparing Inactivated and Live Attenuated Influenza Vaccines*. Vaccines (Basel). 2015;3(2):373–89. doi:10.3390/vaccines3020373.
21. Committee for Proprietary Medicinal Products (CPMP). Note for guidance on harmonisation of requirements for influenza vaccines. CPMP/BWP/214/96. 1997.
22. Committee for Medicinal Products for Human Use (CHMP). Guideline on influenza vaccines. Non-clinical and Clinical module. EMA/CHMP/VWP/457259/2014. 2014.
23. Hannoun C. The evolving history of influenza viruses and influenza vaccines. *Expert Rev Vaccines*. 2013;12(9):1085–94. doi:10.1586/14760584.2013.824709.
24. Muhammad R, Haber P, Broder K, Leroy Z, Ball R, Braun MM, Davis RL, McMahon AW. Adverse events following trivalent inactivated influenza vaccination in children: analysis of the vaccine adverse event reporting system. *Pediatr Infect Dis J*. 2011;30(1):e1–8. doi:10.1097/INF.0b013e3181f9795.
25. Health D. Flu (influenza) vaccine and children: what WA parents need to know. Department of Health Western Australia. 2012. [http://www.health.wa.gov.au/flu/families\\_individuals/children.cfm](http://www.health.wa.gov.au/flu/families_individuals/children.cfm).
26. Li-Kim-Moy J, Yin JK, Rashid H, Khandaker G, King C, Wood N, Macartney KK, Jones C, Booy R. Systematic review of fever, febrile convulsions and serious adverse events following administration of inactivated trivalent influenza vaccines in children. *Euro Surveill*. 2015;20(24):1–10. doi:10.2807/1560-7917.ES2015.20.24.21159.
27. Esposito S, Giavoli C, Trombetta C, Bianchini S, Montinaro V, Spada A, Montomoli E, Principi N. Immunogenicity, safety and tolerability of inactivated trivalent influenza vaccine in overweight and obese children. *Vaccine*. 2016;34(1):56–60. doi:10.1016/j.vaccine.2015.11.019.
28. Ambrose CS, Levin MJ. The rationale for quadrivalent influenza vaccines. *Hum Vaccin Immunother*. 2012;8(1):81–8. doi:10.4161/hv.8.1.17623.
29. Soema PC, Kompier R, Amorij JP, Kersten GF. Current and next generation influenza vaccines: Formulation and production strategies. *Eur J Pharm Biopharm*. 2015;94:251–63. doi:10.1016/j.ejpb.2015.05.023.
30. CDC. Prevention and Control of Influenza with Vaccines: Interim Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2013. *Morb Mortal Wkly Rep*. (MMWR) 2013;62(18):356–356.
31. Greenberg DP, Robertson CA, Noss MJ, Blatter MM, Biedenbender R, Decker MD. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adults. *Vaccine*. 2013;31(5):770–6. doi:10.1016/j.vaccine.2012.11.074.
32. Pepin S, Donazzolo Y, Jambrecina A, Salamand C, Saville M. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine in adults. *Vaccine*. 2013;31(47):5572–8. doi:10.1016/j.vaccine.2013.08.069.
33. Goodwin K, Viboud C, Simonsen L. Antibody response to influenza vaccination in the elderly: a quantitative review. *Vaccine*. 2006;24(8):1159–69. doi:10.1016/j.vaccine.2005.08.105.
34. McElhaney JE, Zhou X, Talbot HK, Soethout E, Bleackley RC, Granville DJ, Pawelec G. The unmet need in the elderly: how immunosenescence, CMV infection, co-morbidities and frailty are a challenge for the development of more effective influenza vaccines. *Vaccine*. 2012;30(12):2060–7. doi:10.1016/j.vaccine.2012.01.015.
35. Beyer WEP, Palache AM, Bouffich M, Osterhaus A. Rationale for two influenza B lineages in seasonal vaccines: A meta-regression study on immunogenicity and controlled field trials. *Vaccine*. 2017;35(33):4167–4176. doi:10.1016/j.vaccine.2017.06.038.
36. Tinoco JC, Pavia-Ruz N, Cruz-Valdez A, Aranza Doniz C, Chandrasekaran V, Dewe W, Liu A, Innis BL, Jain VK. Immunogenicity, reactogenicity, and safety of inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine in healthy adults aged >= 18 years: a phase III, randomized trial. *Vaccine*. 2014;32(13):1480–7. doi:10.1016/j.vaccine.2014.01.022.
37. Regan AK, Tracey L, Gibbs R. Post-marketing surveillance of adverse events following immunization with inactivated quadrivalent and trivalent influenza vaccine in health care providers in Western Australia. *Vaccine*. 2015;33(46):6149–51. doi:10.1016/j.vaccine.2015.10.005.
38. Moa AM, Chughtai AA, Muscatello DJ, Turner RM, MacIntyre CR. Immunogenicity and safety of inactivated quadrivalent influenza vaccine in adults: A systematic review and meta-analysis of randomised controlled trials. *Vaccine*. 2016;34(35):4092–102. doi:10.1016/j.vaccine.2016.06.064.
39. Rodriguez Weber MA, Claeys C, Aranza Doniz C, Feng Y, Innis BL, Jain VK, Peeters M. Immunogenicity and safety of inactivated quadrivalent and trivalent influenza vaccines in children 18–47 months of age. *Pediatr Infect Dis J*. 2014;33(12):1262–9. doi:10.1097/INF.0000000000000463.
40. Haber P, Moro PL, Lewis P, Woo EJ, Jankosky C, Cano M. Post-licensure surveillance of quadrivalent inactivated influenza (IIV4) vaccine in the United States, Vaccine Adverse Event Reporting System (VAERS), July 1, 2013–May 31, 2015. *Vaccine*. 2016;34(22):2507–12. doi:10.1016/j.vaccine.2016.03.048.
41. Cox RJ. Correlates of protection to influenza virus, where do we go from here? *Hum Vaccin Immunother*. 2013;9(2):405–8. doi:10.4161/hv.22908.
42. Isakova-Sivak I, Rudenko L. Safety, immunogenicity and infectivity of new live attenuated influenza vaccines. *Expert Rev Vaccines*. 2015;14(10):1313–29. doi:10.1586/14760584.2015.1075883.
43. Ambrose CS, Luke C, Coelingh K. Current status of live attenuated influenza vaccine in the United States for seasonal and pandemic influenza. *Influenza Other Respir Viruses*. 2008;2(6):193–202. doi:10.1111/j.1750-2659.2008.00056.x.
44. WHO. Global pandemic influenza action plan to increase vaccine supply: progress report 2006–2008. WHO/IVB/09.05. 2009;1–69.
45. Bergen R, Black S, Shinefield H, Lewis E, Ray P, Hansen J, Walker R, Hessel C, Cordova J, Mendelman PM. Safety of cold-adapted live attenuated influenza vaccine in a large cohort of children and adolescents. *Pediatr Infect Dis J*. 2004;23(2):138–44. doi:10.1097/01.inf.0000109392.96411.4f.
46. Ambrose CS, Yi T, Falloon J. An integrated, multistudy analysis of the safety of Ann Arbor strain live attenuated influenza vaccine in children aged 2–17 years. *Influenza Other Respir Viruses*. 2011;5(6):389–97. doi:10.1111/j.1750-2659.2011.00243.x.
47. Esposito S, Montinaro V, Gropali E, Tenconi R, Semino M, Principi N. Live attenuated intranasal influenza vaccine. *Hum Vaccin Immunother*. 2012;8(1):76–80. doi:10.4161/hv.8.1.18809.
48. Belshe RB, Edwards KM, Vesikari T, Black SV, Walker RE, Hultquist M, Kemble G, Connor EM, Group C-TCES. Live attenuated versus inactivated influenza vaccine in infants and young children. *N Engl J Med*. 2007;356(7):685–96. doi:10.1056/NEJMoa065368.
49. Carter NJ, Curran MP. Live attenuated influenza vaccine (FluMist (R); Fluenz): a review of its use in the prevention of seasonal influenza in children and adults. *Drugs*. 2011;71(12):1591–622. doi:10.2165/11206860-000000000-00000.

50. Tennis P, Toback SL, Andrews E, McQuay LJ, Ambrose CS. A post-marketing evaluation of the frequency of use and safety of live attenuated influenza vaccine use in nonrecommended children younger than 5 years. *Vaccine*. 2011;29(31):4947–52. doi:10.1016/j.vaccine.2011.04.113.
51. Baxter R, Toback SL, Sifakis F, Hansen J, Bartlett J, Aukes L, Lewis N, Wu X, Ambrose CS. A postmarketing evaluation of the safety of Ann Arbor strain live attenuated influenza vaccine in adults 18–49 years of age. *Vaccine*. 2012;30(20):3053–60. doi:10.1016/j.vaccine.2012.02.080.
52. Kelso JM. Safety of influenza vaccines. *Curr Opin Allergy Clin Immunol*. 2012;12(4):383–8. doi:10.1097/ACI.0b013e328354395d.
53. Tennis P, Toback SL, Andrews EB, McQuay LJ, Ambrose CS. A US postmarketing evaluation of the frequency and safety of live attenuated influenza vaccine use in nonrecommended children younger than 5 years: 2009–2010 season. *Vaccine*. 2012;30(42):6099–102. doi:10.1016/j.vaccine.2012.07.031.
54. Vesikari T, Karvonen A, Korhonen T, Edelman K, Vainionpää R, Salmi A, Saville MK, Cho I, Razmpour A, Rappaport R, et al. A randomized, double-blind study of the safety, transmissibility and phenotypic and genotypic stability of cold-adapted influenza virus vaccine. *Pediatr Infect Dis J*. 2006;25(7):590–5. doi:10.1097/01.inf.0000220229.51531.47.
55. Belshe RB, Gruber B, Mendelman PM, Mehta HB, Mahmood K, Reisinger K, Treanor J, Zangwill K, Hayden FG, Bernstein DI, et al. Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. *J Infect Dis*. 2000;181(3):1133–7. doi:10.1086/315323.
56. JCVI. JCVI statement on the annual influenza vaccination programme – extension of the programme to children. 2012;1–6.
57. McNaughton R, Lynn E, Osborne V, Coughtrie A, Layton D, Shakir S. Safety of Intranasal Quadrivalent Live Attenuated Influenza Vaccine (QLAIV) in Children and Adolescents: A Pilot Prospective Cohort Study in England. *Drug Saf*. 2016;39(4):323–33. doi:10.1007/s40264-015-0384-7.
58. Stockwell MS, Broder KR, Lewis P, Jakob K, Iqbal S, Fernandez N, Sharma D, Barrett A, LaRussa P. Assessing Fever Frequency After Pediatric Live Attenuated Versus Inactivated Influenza Vaccination. *J Pediatric Infect Dis Soc*. 2017. 6(3):e7–e14.
59. Carr S, Allison KJ, Van De Velde LA, Zhang K, English EY, Iverson A, Daw NC, Howard SC, Navid F, Rodriguez-Galindo C, et al. Safety and immunogenicity of live attenuated and inactivated influenza vaccines in children with cancer. *J Infect Dis*. 2011;204(10):1475–82. doi:10.1093/infdis/jir561.
60. King JCI Jr, Treanor J, Fast PE, Wolff M, Yan L, Iacuzio D, Readmond B, O'Brien D, Mallon K, Highsmith WE, et al. Comparison of the safety, vaccine virus shedding, and immunogenicity of influenza virus vaccine, trivalent, types A and B, live cold-adapted, administered to human immunodeficiency virus (HIV)-infected and non-HIV-infected adults. *J Infect Dis*. 2000;181(2):725–8. doi:10.1086/315246.
61. Mohn KG, Smith I, Sjursen H, Cox R. Immune responses after live attenuated influenza vaccination. *Hum Vaccin Immunother*. 2017;0. doi:10.1080/21645515.2017.1377376.
62. Caspard H, Gaglani M, Clipper L, Belongia EA, McLean HQ, Griffin MR, Talbot HK, Poehling KA, Peters TR, Veney N, et al. Effectiveness of live attenuated influenza vaccine and inactivated influenza vaccine in children 2–17 years of age in 2013–2014 in the United States. *Vaccine*. 2016;34(1):77–82. doi:10.1016/j.vaccine.2015.11.010.
63. CDC. Frequently Asked Flu Questions 2017–2018 Influenza Season. 2017. <https://www.cdc.gov/flu/about/season/flu-season-2017-2018.htm>.
64. Mameli C, D'Auria E, Erba P, Nannini P, Zuccotti GV. Influenza vaccine response: future perspectives. *Expert Opin Biol Ther*. 2017;1–5.
65. Turner PJ, Southern J, Andrews NJ, Miller EM, Erlewyn-Lajunesse, and S.-S. Investigators, Safety of live attenuated influenza vaccine in young people with egg allergy: multicentre prospective cohort study. *BMJ*. 2015;351:h6291. doi:10.1136/bmj.h6291.
66. Moorman JE, Rudd RA, Johnson CA, King M, Minor P, Bailey C, Scalia MR, Akinbami LJ, Centers C. for Disease, and Prevention, National surveillance for asthma—United States, 1980–2004. *MMWR Surveill Summ*. 2007;56(8):1–54.
67. Rudd RA, Moorman JE. Asthma incidence: data from the National Health Interview Survey, 1980–1996. *J Asthma*. 2007;44(1):65–70. doi:10.1080/02770900601125896.
68. Eggesbo M, Botten G, Halvorsen R, Magnus P. The prevalence of allergy to egg: a population-based study in young children. *Allergy*. 2001;56(5):403–11. doi:10.1034/j.1398-9995.2001.056005403.x.
69. Davies R, Pepys J. Egg allergy, influenza vaccine, and immunoglobulin E antibody. *J Allergy Clin Immunol*. 1976;57(4):373–83. doi:10.1016/0091-6749(76)90095-6.
70. Bierman CW, Shapiro GG, Pierson WE, Taylor JW, Foy HM, Fox JP. Safety of influenza vaccination in allergic children. *J Infect Dis*. 1977;136(Suppl):S652–5. doi:10.1093/infdis/136.Supplement\_3.S652.
71. Miller JR, Orgel HA, Meltzer EO. The safety of egg-containing vaccines for egg-allergic patients. *J Allergy Clin Immunol*. 1983;71(6):568–73. doi:10.1016/0091-6749(83)90438-4.
72. Murphy KR, Strunk RC. Safe administration of influenza vaccine in asthmatic children hypersensitive to egg proteins. *J Pediatr*. 1985;106(6):931–3. doi:10.1016/S0022-3476(85)80241-9.
73. Zeiger RS. Current issues with influenza vaccination in egg allergy. *J Allergy Clin Immunol*. 2002;110(6):834–40. doi:10.1067/mai.2002.129372.
74. Kelso JM, Li JT, Nicklas RA, Blessing-Moore J, Cox L, Lang DM, Oppenheimer J, Portnoy JM, Randolph C, Schuller DE, et al. P. Joint Task Force on Practice, A. Joint Task Force on Practice Parameters for, and Immunology, Adverse reactions to vaccines. *Ann Allergy Asthma Immunol*. 2009;103(4 Suppl 2):S1–14. doi:10.1016/S1081-1206(10)60350-X.
75. Chung EY, Huang L, Schneider L. Safety of influenza vaccine administration in egg-allergic patients. *Pediatrics*. 2010;125(5):e1024–30. doi:10.1542/peds.2009-2512.
76. Ambrose CS, Wu X, Knuf M, Wutzler P. The efficacy of intranasal live attenuated influenza vaccine in children 2 through 17 years of age: a meta-analysis of 8 randomized controlled studies. *Vaccine*. 2012;30(5):886–92. doi:10.1016/j.vaccine.2011.11.104.
77. Belshe RB, Ambrose CS, Yi T. Safety and efficacy of live attenuated influenza vaccine in children 2–7 years of age. *Vaccine*. 2008;26(Suppl 4):D10–6. doi:10.1016/j.vaccine.2008.06.083.
78. Gaglani MJ, Piedra PA, Riggs M, Herschler G, Fewlass C, Glezen WP. Safety of the intranasal, trivalent, live attenuated influenza vaccine (LAIV) in children with intermittent wheezing in an open-label field trial. *Pediatr Infect Dis J*. 2008;27(5):444–52. doi:10.1097/INF.0b013e3181660c2e.
79. Grohskopf LA, Sokolow LZ, Olsen SJ, Bresee JS, Broder KR, Karron RA. Prevention and Control of Influenza With Vaccines: Recommendations of the Advisory Committee on Immunization Practices, United States, 2015–16 Influenza Season. *Am J Transplant*. 2015;15(10):2767–75. doi:10.1111/ajt.13505.
80. Iskander J, Broder K. Monitoring the safety of annual and pandemic influenza vaccines: lessons from the US experience. *Expert Rev Vaccines*. 2008;7(1):75–82. doi:10.1586/14760584.7.1.75.
81. Hurwitz ES, Schonberger LB, Nelson DB, Holman RC. Guillain-Barre syndrome and the 1978–1979 influenza vaccine. *N Engl J Med*. 1981;304(26):1557–61. doi:10.1056/NEJM198106253042601.
82. Safranek TJ, Lawrence DN, Kurland LT, Culver DH, Wiederholt WC, Hayner NS, Osterholm MT, O'Brien P, Hughes JM. Reassessment of the association between Guillain-Barre syndrome and receipt of swine influenza vaccine in 1976–1977: results of a two-state study. *Expert Neurology Group*. *Am J Epidemiol*. 1991;133(9):940–51. doi:10.1093/oxfordjournals.aje.a115973.
83. Lasky T, Terracciano GJ, Magder L, Koski CL, Ballesteros M, Nash D, Clark S, Haber P, Stolley PD, Schonberger LB, et al. The Guillain-Barre syndrome and the 1992–1993 and 1993–1994 influenza vaccines. *N Engl J Med*. 1998;339(25):1797–802. doi:10.1056/NEJM199812173392501.
84. Salmon DA, Proschan M, Forshee R, Gargiullo P, Bleser W, Burwen DR, Cunningham F, Garman P, Greene SK, Lee GM,

- et al. HNGM-AW. Group. Association between Guillain-Barre syndrome and influenza A (H1N1) 2009 monovalent inactivated vaccines in the USA: a meta-analysis. *Lancet*. 2013;381(9876):1461–8. doi:10.1016/S0140-6736(12)62189-8.
85. Dodd CN, Romio SA, Black S, Vellozzi C, Andrews N, Sturkenboom M, Zuber P, Hua W, Bonhoeffer J, Buttery J, et al. H.N.G. B.S.C. Global. International collaboration to assess the risk of Guillain Barre Syndrome following Influenza A (H1N1) 2009 monovalent vaccines. *Vaccine*. 2013;31(40):4448–58. doi:10.1016/j.vaccine.2013.06.032.
  86. Martin Arias LH, Sanz R, Sainz M, Treceno C, Carvajal A. Guillain-Barre syndrome and influenza vaccines: A meta-analysis. *Vaccine*. 2015;33(31):3773–8. doi:10.1016/j.vaccine.2015.05.013.
  87. Wu J, Xu F, Lu L, Lu M, Miao L, Gao T, Ji W, Suo L, Liu D, Ma R, et al. Safety and effectiveness of a 2009 H1N1 vaccine in Beijing. *N Engl J Med*. 2010;363(25):2416–23. doi:10.1056/NEJMoa1006736.
  88. Bardage C, Persson I, Ortvist A, Bergman U, Ludvigsson JF, Granath F. Neurological and autoimmune disorders after vaccination against pandemic influenza A (H1N1) with a monovalent adjuvanted vaccine: population based cohort study in Stockholm, Sweden. *BMJ*. 2011;343:d5956. doi:10.1136/bmj.d5956.
  89. Ghaderi S, Gunnes N, Bakken IJ, Magnus P, Trogstad L, Haberg SE. Risk of Guillain-Barre syndrome after exposure to pandemic influenza A(H1N1)pdm09 vaccination or infection: a Norwegian population-based cohort study. *Eur J Epidemiol*. 2016;31(1):67–72. doi:10.1007/s10654-015-0047-0.
  90. Burwen DR, Sandhu SK, MaCurdy TE, Kelman JA, Gibbs JM, Garcia B, Markatou M, Forshee RA, Izurieta HS, Ball R. G. Safety Surveillance Working, Surveillance for Guillain-Barre syndrome after influenza vaccination among the Medicare population, 2009–2010. *Am J Public Health*. 2012;102(10):1921–7.
  91. Alcalde-Cabero E, Almazan-Isla J, Garcia Lopez FJ, Ara-Callizo JR, Avellanal F, Casasnovas C, Cemillan C, Cuadrado JJ, Duarte J, Fernandez-Perez MD, et al. G.B.S.E.S.G. Spanish, Guillain-Barre syndrome following the 2009 pandemic monovalent and seasonal trivalent influenza vaccination campaigns in Spain from 2009 to 2011: outcomes from active surveillance by a neurologist network, and records from a country-wide hospital discharge database. *BMC Neurol*. 2016;16:75. doi:10.1186/s12883-016-0598-z.
  92. Ahmed SS, Montomoli E, Pasini FL, Steinman L. The Safety of Adjuvanted Vaccines Revisited: Vaccine-Induced Narcolepsy. *Isr Med Assoc J*. 2016;18(3-4):216–20.
  93. Medical Products Agency (MPA). The MPA investigates reports of narcolepsy in patients vaccinated with Pandemrix. 2010.
  94. Nohynek H, Jokinen J, Partinen M, Vaarala O, Kirjavainen T, Sundman J, Himanen SL, Hublin C, Julkunen I, Olsen P, et al. AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland. *PLoS One*. 2012;7(3):e33536. doi:10.1371/journal.pone.0033536.
  95. Partinen M, Saarenpaa-Heikkila O, Ilveskoski I, Hublin C, Linna M, Olsen P, Nokelainen P, Alen R, Wallden T, Espo M, et al. Increased incidence and clinical picture of childhood narcolepsy following the 2009 H1N1 pandemic vaccination campaign in Finland. *PLoS One*. 2012;7(3):e33723. doi:10.1371/journal.pone.0033723.
  96. Dauvilliers Y, Arnulf I, Lécendreux M, Monaca Charley C, Franco P, Drouot X, d'Ortho MP, Launois S, Lignot S, et al. V.F.s.g. Narcoflu, Increased risk of narcolepsy in children and adults after pandemic H1N1 vaccination in France. *Brain*. 2013;136(Pt 8):2486–96. doi:10.1093/brain/awt187.
  97. Ahmed SS, Volkmueth W, Duca J, Corti L, Pallaoro M, Pezzicoli A, Karle A, Rigat F, Rappuoli R, Narasimhan V, et al. Antibodies to influenza nucleoprotein cross-react with human hypocretin receptor 2. *Sci Transl Med*. 2015;7(294):294ra105. doi:10.1126/scitranslmed.aab2354.
  98. Oberle D, Pavel J, Rieck T, Weichert S, Schrotten H, Keller-Stanislawski B, Tenenbaum T. Anaphylaxis After Immunization of Children and Adolescents in Germany. *Pediatr Infect Dis J*. 2016;35(5):535–41. doi:10.1097/INF.0000000000001073.
  99. Trombetta CM, Perini D, Mather S, Temperton N, Montomoli E. Overview of Serological Techniques for Influenza Vaccine Evaluation: Past, Present and Future. *Vaccines (Basel)*. 2014;2(4):707–34. doi:10.3390/vaccines2040707.
  100. EMA. Interim guidance on enhanced safety surveillance for seasonal influenza vaccines in the EU. EMA/PRAC/222346/2014. 2014;1–10.
  101. Neuzil KM, Edwards KM. Influenza vaccines in children. *Semin Pediatr Infect Dis*. 2002;13(3):174–81. doi:10.1053/spid.2002.125860.
  102. Esposito S, Tagliabue C, Tagliaferri L, Semino M, Longo MR, Principi N. Preventing influenza in younger children. *Clin Microbiol Infect*. 2012;18(Suppl 5):42–9. doi:10.1111/j.1469-0691.2012.03942.x.
  103. CDC. Flu Symptoms & Complications. 2016.
  104. Heikkinen T, Heinonen S. Effectiveness and safety of influenza vaccination in children: European perspective. *Vaccine*. 2011;29(43):7529–34. doi:10.1016/j.vaccine.2011.08.011.
  105. Monto AS. Seasonal influenza and vaccination coverage. *Vaccine*. 2010;28(Suppl 4):D33–44. doi:10.1016/j.vaccine.2010.08.027.
  106. Shen Y, Hu Y, Meng F, Du W, Li W, Song Y, Ji X, Huo L, Fu Z, Yin W. Safety, immunogenicity and cross-reactivity of a Northern hemisphere 2013–2014 seasonal trivalent inactivated split influenza virus vaccine, Anflu(R). *Hum Vaccin Immunother*. 2016;12(5):1229–34. doi:10.1080/21645515.2015.1123357.
  107. Halasa NB, Gerber MA, Berry AA, Anderson EL, Winokur P, Keyserling H, Eckard AR, Hill H, Wolff MC, McNeal MM, et al. Safety and Immunogenicity of Full-Dose Trivalent Inactivated Influenza Vaccine (TIV) Compared With Half-Dose TIV Administered to Children 6 Through 35 Months of Age. *J Pediatric Infect Dis Soc*. 2015;4(3):214–24. doi:10.1093/jpids/piu061.
  108. Skowronski DM, Hottes TS, Chong M, De Serres G, Scheifele DW, Ward BJ, Halperin SA, Janjua NZ, Chan T, Sabaiduc S, et al. Randomized controlled trial of dose response to influenza vaccine in children aged 6 to 23 months. *Pediatrics*. 2011;128(2):e276–89. doi:10.1542/peds.2010-2777.
  109. Pavia-Ruz N, Angel Rodriguez Weber M, Lau YL, Nelson EA, Kerdpnich A, Huang LM, Silas P, Qaundah P, Blatter M, Jeanfreau R, et al. A randomized controlled study to evaluate the immunogenicity of a trivalent inactivated seasonal influenza vaccine at two dosages in children 6 to 35 months of age. *Hum Vaccin Immunother*. 2013;9(9):1978–88. doi:10.4161/hv.25363.
  110. Langley JM, Vanderkooi OG, Garfield HA, Hebert J, Chandrasekaran V, Jain VK, Fries L. Immunogenicity and Safety of 2 Dose Levels of a Thimerosal-Free Trivalent Seasonal Influenza Vaccine in Children Aged 6–35 Months: A Randomized, Controlled Trial. *J Pediatric Infect Dis Soc*. 2012;1(1):55–63. doi:10.1093/jpids/pis012.
  111. Vesikari T, Block SL, Guerra F, Lattanzi M, Holmes S, Izu A, Gaitatzis N, Hilbert AK, Groth N. Immunogenicity, safety and reactogenicity of a mammalian cell-culture-derived influenza vaccine in healthy children and adolescents three to seventeen years of age. *Pediatr Infect Dis J*. 2012;31(5):494–500. doi:10.1097/INF.0b013e31824bb179.
  112. Nolan T, Chotpitayasunondh T, Capeding MR, Carson S, Senders SD, Jaehnig P, de Rooij R, Chandra R. Safety and tolerability of a cell culture derived trivalent subunit inactivated influenza vaccine administered to healthy children and adolescents: A Phase III, randomized, multicenter, observer-blind study. *Vaccine*. 2016;34(2):230–6. doi:10.1016/j.vaccine.2015.11.040.
  113. Esposito S, Daleno C, Piccioli I, Tagliaferri L, Scala A, Prunotto G, Montinaro V, Galeone C, Principi N. Immunogenicity and safety of intradermal influenza vaccine in children. *Vaccine*. 2011;29(44):7606–10. doi:10.1016/j.vaccine.2011.08.021.
  114. Vesikari T, Groth N, Karvonen A, Borkowski A, Pellegrini M. MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination. *Vaccine*. 2009;27(45):6291–5. doi:10.1016/j.vaccine.2009.02.004.
  115. Carmona Martinez A, Salamanca de la Cueva I, Boutet P, Vanden Abeele C, Smolenov I, Devaster JM. A phase 1, open-label safety and immunogenicity study of an AS03-adjuvanted trivalent inactivated influenza vaccine in children aged 6 to 35 months. *Hum Vaccin Immunother*. 2014;10(7):1959–68. doi:10.4161/hv.28743.
  116. Nolan T, Bravo L, Ceballos A, Mitha E, Gray G, Quiambao B, Patel SS, Bizjajeva S, Bock H, Nazaire-Bermal N, et al. Enhanced and

- persistent antibody response against homologous and heterologous strains elicited by a MF59-adjuvanted influenza vaccine in infants and young children. *Vaccine*. 2014;32(46):6146–56. doi:10.1016/j.vaccine.2014.08.068.
117. Vesikari T, Forsten A, Arora A, Tsai T, Clemens R. Influenza vaccination in children primed with MF59-adjuvanted or non-adjuvanted seasonal influenza vaccine. *Hum Vaccin Immunother*. 2015;11(8):2102–12. doi:10.1080/21645515.2015.1044167.
  118. Black S, Della Cioppa G, Malfroot A, Nacci P, Nicolay U, Pellegrini M, Sokal E, Vertruyen A. Safety of MF59-adjuvanted versus non-adjuvanted influenza vaccines in children and adolescents: an integrated analysis. *Vaccine*. 2010;28(45):7331–6. doi:10.1016/j.vaccine.2010.08.075.
  119. Manini I, Domnich A, Amicizia D, Rossi S, Pozzi T, Gasparini R, Panatto D, Montomoli E. Flucelvax (Optafu) for seasonal influenza. *Expert Rev Vaccines*. 2015;14(6):789–804. doi:10.1586/14760584.2015.1039520.
  120. Langley JM, Wang L, Aggarwal N, Bueso A, Chandrasekaran V, Cousin L, Halperin SA, Li P, Liu A, McNeil S, et al. Immunogenicity and Reactogenicity of an Inactivated Quadrivalent Influenza Vaccine Administered Intramuscularly to Children 6 to 35 Months of Age in 2012–2013: A Randomized, Double-Blind, Controlled, Multicenter, Multicountry, Clinical Trial. *J Pediatric Infect Dis Soc*. 2015;4(3):242–51. doi:10.1093/jpids/piu098.
  121. Wang L, Chandrasekaran V, Domachowske JB, Li P, Innis BL, Jain VK. Immunogenicity and Safety of an Inactivated Quadrivalent Influenza Vaccine in US Children 6–35 Months of Age During 2013–2014: Results From A Phase II Randomized Trial. *J Pediatric Infect Dis Soc*. 2016;5(2):170–9. doi:10.1093/jpids/piv041.
  122. Belshe RB, Mendelman PM, Treanor J, King J, Gruber WC, Piedra P, Bernstein DI, Hayden FG, Kotloff K, Zangwill K, et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine in children. *N Engl J Med*. 1998;338(20):1405–12. doi:10.1056/NEJM199805143382002.
  123. Klick B, Durrani S, Chan KH, Ip DK, Chou ES, Kwok HK, Ng S, Chiu SS, Peiris JS, Leung GM, et al. Live attenuated seasonal and pandemic influenza vaccine in school-age children: a randomized controlled trial. *Vaccine*. 2013;31(15):1937–43. doi:10.1016/j.vaccine.2013.02.017.
  124. Baxter R, Eaton A, Hansen J, Aukes L, Caspard H, Ambrose CS. Safety of quadrivalent live attenuated influenza vaccine in subjects aged 2–49 years. *Vaccine*. 2017;35(9):1254–1258. doi:10.1016/j.vaccine.2017.01.062.
  125. WHO. Recommendations and laboratory procedures for detection of avian influenza A(H5N1) virus in specimens from suspected human cases. 2007:1–28.
  126. Garcia-Sicilia J, Aristegui J, Omenaca F, Carmona A, Tejedor JC, Merino JM, Garcia-Corbeira P, Walravens K, Bambure V, Moris P, et al. Safety and persistence of the humoral and cellular immune responses induced by 2 doses of an AS03-adjuvanted A (H1N1)pdm09 pandemic influenza vaccine administered to infants, children and adolescents: Two open, uncontrolled studies. *Hum Vaccin Immunother*. 2015;11(10):2359–69. doi:10.1080/21645515.2015.1063754.
  127. Lu CY, Shao PL, Chang LY, Huang YC, Chiu CH, Hsieh YC, Lin TY, Huang LM. Immunogenicity and safety of a monovalent vaccine for the 2009 pandemic influenza virus A (H1N1) in children and adolescents. *Vaccine*. 2010;28(36):5864–70. doi:10.1016/j.vaccine.2010.06.059.
  128. Knuf M, Leroux-Roels G, Rumke HC, Abarca K, Rivera L, Lattanzi M, Pedotti P, Arora A, Kieninger-Baum D, Della Cioppa G. Safety and immunogenicity of an MF59-adjuvanted A/H1N1 pandemic influenza vaccine in children from three to seventeen years of age. *Vaccine*. 2015;33(1):174–81. doi:10.1016/j.vaccine.2014.10.085.
  129. Scheifele DW, Ward BJ, Dionne M, Vanderkooi O, Langley JM, Dobson S, Li Y, Law B, Halperin SA. I. Public Health Agency of Canada/Canadian Institutes of Health Research Influenza Research Network Rapid Trials, Evaluation of adjuvanted pandemic H1N1(2009) influenza vaccine after one and two doses in young children. *Pediatr Infect Dis J*. 2011;30(5):402–7. doi:10.1097/INF.0b013e3182068f33.
  130. Nolan T, Roy-Ghanta S, Montellano M, Weckx L, Ulloa-Gutierrez R, Lazcano-Ponce E, Kerdpanich A, Safadi MA, Cruz-Valdez A, Litao S, et al. Relative efficacy of AS03-adjuvanted pandemic influenza A(H1N1) vaccine in children: results of a controlled, randomized efficacy trial. *J Infect Dis*. 2014;210(4):545–57. doi:10.1093/infdis/jiu173.
  131. Plennevaux E, Sheldon E, Blatter M, Reeves-Hoche MK, Denis M. Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials. *Lancet*. 2010;375(9708):41–8. doi:10.1016/S0140-6736(09)62026-2.
  132. Knuf M, Leroux-Roels G, Rumke H, Rivera L, Pedotti P, Arora AK, Lattanzi M, Kieninger D, Cioppa GD. Immunogenicity and safety of cell-derived MF59(R)-adjuvanted A/H1N1 influenza vaccine for children. *Hum Vaccin Immunother*. 2015;11(2):358–76. doi:10.4161/21645515.2014.987014.
  133. Diez-Domingo J, Baldo JM, Planelles-Catarino MV, Garces-Sanchez M, Ubeda I, Jubert-Rosich A, Mares J, Garcia-Corbeira P, Moris P, Teko M, et al. Phase II, randomized, open, controlled study of AS03-adjuvanted H5N1 pre-pandemic influenza vaccine in children aged 3 to 9 years: follow-up of safety and immunogenicity persistence at 24 months post-vaccination. *Influenza Other Respir Viruses*. 2015;9(2):68–77. doi:10.1111/irv.12295.
  134. WHO. Weekly epidemiological record. Vaccines against influenza WHO position paper –November 2012. 2012:461–76.
  135. Michiels B, Govaerts F, Remmen R, Vermeire E, Coenen S. A systematic review of the evidence on the effectiveness and risks of inactivated influenza vaccines in different target groups. *Vaccine*. 2011;29(49):9159–70. doi:10.1016/j.vaccine.2011.08.008.
  136. Kieninger D, Sheldon E, Lin WY, Yu CJ, Bayas JM, Gabor JJ, Esen M, Fernandez Roure JL, Narejos Perez S, Alvarez Sanchez C, et al. Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged >= 18 years. *BMC Infect Dis*. 2013;13:343. doi:10.1186/1471-2334-13-343.
  137. Gorse GJ, Falsey AR, Johnson CM, Morrison D, Fried DL, Ervin JE, Greenberg DP, Ozol-Godfrey A, Landolfi V, Tsang PH. Safety and immunogenicity of revaccination with reduced dose intradermal and standard dose intramuscular influenza vaccines in adults 18–64 years of age. *Vaccine*. 2013;31(50):6034–40. doi:10.1016/j.vaccine.2013.09.012.
  138. Frey SE, Reyes MR, Reynales H, Bernal NN, Nicolay U, Narasimhan V, Forleo-Neto E, Arora AK. Comparison of the safety and immunogenicity of an MF59(R)-adjuvanted with a non-adjuvanted seasonal influenza vaccine in elderly subjects. *Vaccine*. 2014;32(39):5027–34. doi:10.1016/j.vaccine.2014.07.013.
  139. Mo Z, Nong Y, Liu S, Shao M, Liao X, Go K, Lavis N. Immunogenicity and safety of a trivalent inactivated influenza vaccine produced in Shenzhen, China. *Hum Vaccin Immunother*. 2017;13(6):1–7. doi:10.1080/21645515.2017.1285475.
  140. Song JY, Cheong HJ, Lee J, Woo HJ, Wie SH, Lee JS, Kim SW, Noh JY, Choi WS, Kim H, et al. Immunogenicity and safety of a cell culture-derived inactivated trivalent influenza vaccine (NBP607): A randomized, double-blind, multi-center, phase 3 clinical trial. *Vaccine*. 2015;33(41):5437–44. doi:10.1016/j.vaccine.2015.08.030.
  141. Roggelin L, Vinnemeier CD, Meyer S, Witte K, Marx L, Theess W, Burchard GD, Rolling T, Cramer JP. A 2013/2014 northern hemisphere season surface antigen inactivated trivalent influenza vaccine—Assessing the immunogenicity and safety in an open label, uncontrolled study. *Hum Vaccin Immunother*. 2015;11(10):2370–5. doi:10.1080/21645515.2015.1064570.
  142. Groth N, Montomoli E, Gentile C, Manini I, Bugarini R, Podda A. Safety, tolerability and immunogenicity of a mammalian cell-culture-derived influenza vaccine: a sequential Phase I and Phase II clinical trial. *Vaccine*. 2009;27(5):786–91. doi:10.1016/j.vaccine.2008.11.003.
  143. DiazGranados CA, Saway W, Gouaux J, Baron M, Baker J, Denis M, Jordanov E, Landolfi V, Yau E. Safety and immunogenicity of high-dose trivalent inactivated influenza vaccine in adults 50–64 years of age. *Vaccine*. 2015;33(51):7188–93. doi:10.1016/j.vaccine.2015.10.131.

144. Tsurudome Y, Kimachi K, Okada Y, Matsuura K, Ooyama Y, Ibaragi K, Kino Y, Ueda K. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine in healthy adults: a phase II, open-label, uncontrolled trial in Japan. *Microbiol Immunol.* 2015;59(10):597–604. doi:10.1111/1348-0421.12316.
145. Bart S, Cannon K, Herrington D, Mills R, Forleo-Neto E, Lindert K, Abdul Mateen A. Immunogenicity and safety of a cell culture-based quadrivalent influenza vaccine in adults: A Phase III, double-blind, multicenter, randomized, non-inferiority study. *Hum Vaccin Immunother.* 2016;12(9):2278–88. doi:10.1080/21645515.2016.1182270.
146. Treanor JT, Albano FR, Sawlwin DC, Graves Jones A, Airey J, Formica N, Matassa V, Leong J. Immunogenicity and safety of a quadrivalent inactivated influenza vaccine compared with two trivalent inactivated influenza vaccines containing alternate B strains in adults: A phase 3, randomized noninferiority study. *Vaccine.* 2017;35(15):1856–1864. doi:10.1016/j.vaccine.2017.02.066.
147. Izikson R, Leffell DJ, Bock SA, Patriarca PA, Post P, Dunkle LM, Cox MM. Randomized comparison of the safety of Flublok(R) versus licensed inactivated influenza vaccine in healthy, medically stable adults  $\geq$  50 years of age. *Vaccine.* 2015;33(48):6622–8. doi:10.1016/j.vaccine.2015.10.097.
148. Kaka AS, Filice GA, Myllenbeck S, Nichol KL. Comparison of Side Effects of the 2015–2016 High-Dose, Inactivated, Trivalent Influenza Vaccine and Standard Dose, Inactivated, Trivalent Influenza Vaccine in Adults  $\geq$  65 Years. *Open Forum Infect Dis.* 2017;4(1):ofx001. doi:10.1093/ofid/ofx001.
149. Wilkinson K, Wei Y, Szwajcer A, Rabbani R, Zarychanski R, Abou-Setta AM, Mahmud SM. Efficacy and safety of high-dose influenza vaccine in elderly adults: A systematic review and meta-analysis. *Vaccine.* 2017;35(21):2775–2780. doi:10.1016/j.vaccine.2017.03.092.
150. Tsang TK, Cauchemez S, Perera RA, Freeman G, Fang VJ, Ip DK, Leung GM, Malik Peiris JS, Cowling BJ. Association between antibody titers and protection against influenza virus infection within households. *J Infect Dis.* 2014;210(5):684–92. doi:10.1093/infdis/jiu186.
151. Arakane R, Nakatani H, Fujisaki E, Takahama A, Ishida K, Yoshiike M, Nakayama T, Takeshita F. Immunogenicity and safety of the new intradermal influenza vaccine in adults and elderly: A randomized phase 1/2 clinical trial. *Vaccine.* 2015;33(46):6340–50. doi:10.1016/j.vaccine.2015.09.010.
152. Pileggi C, Lotito F, Bianco A, Nobile CG, Pavia M. Immunogenicity and safety of intradermal influenza vaccine in immunocompromized patients: a meta-analysis of randomized controlled trials. *BMC Infect Dis.* 2015;15:427. doi:10.1186/s12879-015-1161-z.
153. Chi RC, Rock MT, Neuzil KM. Immunogenicity and safety of intradermal influenza vaccination in healthy older adults. *Clin Infect Dis.* 2010;50(10):1331–8. doi:10.1086/652144.
154. Nichol KL, Mendelman PM, Mallon KP, Jackson LA, Gorse GJ, Belshe RB, Glezen WP, Wittes J. Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial. *JAMA.* 1999;282(2):137–44. doi:10.1001/jama.282.2.137.
155. De Villiers PJ, Steele AD, Hiemstra LA, Rappaport R, Dunning AJ, Gruber WC, Forrest BD, L.E.S.T. Network. Efficacy and safety of a live attenuated influenza vaccine in adults 60 years of age and older. *Vaccine.* 2009;28(1):228–34. doi:10.1016/j.vaccine.2009.09.092.
156. Forrest BD, Steele AD, Hiemstra L, Rappaport R, Ambrose CS, Gruber WC. A prospective, randomized, open-label trial comparing the safety and efficacy of trivalent live attenuated and inactivated influenza vaccines in adults 60 years of age and older. *Vaccine.* 2011;29(20):3633–9. doi:10.1016/j.vaccine.2011.03.029.
157. Block SL, Yi T, Sheldon E, Dubovsky F, Falloon J. A randomized, double-blind noninferiority study of quadrivalent live attenuated influenza vaccine in adults. *Vaccine.* 2011;29(50):9391–7. doi:10.1016/j.vaccine.2011.09.109.
158. Zhu FC, Wang H, Fang HH, Yang JG, Lin XJ, Liang XF, Zhang XF, Pan HX, Meng FY, Hu YM, et al. A novel influenza A (H1N1) vaccine in various age groups. *N Engl J Med.* 2009;361(25):2414–23. doi:10.1056/NEJMoa0908535.
159. Clark TW, Pareek M, Hoschler K, Dillon H, Nicholson KG, Groth N, Stephenson I. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. *N Engl J Med.* 2009;361(25):2424–35. doi:10.1056/NEJMoa0907650.
160. Fukase H, Furuie H, Yasuda Y, Komatsu R, Matsushita K, Minami T, Suehiro Y, Yotsuyanagi H, Kusadokoro H, Sawata H, et al. Assessment of the immunogenicity and safety of varying doses of an MF59 (R)-adjuvanted cell culture-derived A/H1N1 pandemic influenza vaccine in Japanese paediatric, adult and elderly subjects. *Vaccine.* 2012;30(33):5030–7. doi:10.1016/j.vaccine.2012.03.053.
161. Greenberg ME, Lai MH, Hartel GF, Wichems CH, Gittleson C, Bennet J, Dawson G, Hu W, Leggio C, Washington D, et al. Response to a monovalent 2009 influenza A (H1N1) vaccine. *N Engl J Med.* 2009;361(25):2405–13. doi:10.1056/NEJMoa0907413.
162. Kubavat AH, Mittal R, Patel PM, Jarsaniya DH, Pawar PR. H.N.V.S. Group. A clinical trial to assess the immunogenicity and safety of Inactivated Influenza Vaccine (Whole Virion) IP (Pandemic Influenza (H1N1) 2009 Monovalent Vaccine; VaxiFlu-S) in healthy Indian adult population. *J Postgrad Med.* 2011;57(2):102–8. doi:10.4103/0022-3859.81860.
163. Hatz C, Cramer JP, Vertruyen A, Schwarz TF, von Sonnenburg F, Borkowski A, Lattanzi M, Hilbert AK, Cioppa GD, Leroux-Roels G. A randomised, single-blind, dose-range study to assess the immunogenicity and safety of a cell-culture-derived A/H1N1 influenza vaccine in adult and elderly populations. *Vaccine.* 2012;30(32):4820–7. doi:10.1016/j.vaccine.2012.05.013.
164. Reisinger KS, Holmes SJ, Pedotti P, Arora AK, Lattanzi M. A dose-ranging study of MF59(R)-adjuvanted and non-adjuvanted A/H1N1 pandemic influenza vaccine in young to middle-aged and older adult populations to assess safety, immunogenicity, and antibody persistence one year after vaccination. *Hum Vaccin Immunother.* 2014;10(8):2395–407. doi:10.4161/hv.29393.
165. Sobhanie M, Matsuoka Y, Jegaskanda S, Fitzgerald T, Mallory R, Chen Z, Luke C, Treanor J, Subbarao K. Evaluation of the Safety and Immunogenicity of a Candidate Pandemic Live Attenuated Influenza Vaccine (pLAIV) Against Influenza A(H7N9). *J Infect Dis.* 2016;213(6):922–9. doi:10.1093/infdis/jiv526.
166. Vesikari T, Forsten A, Herbingier KH, Cioppa GD, Beygo J, Borkowski A, Groth N, Bennati M, von Sonnenburg F. Safety and immunogenicity of an MF59(R)-adjuvanted A/H5N1 pre-pandemic influenza vaccine in adults and the elderly. *Vaccine.* 2012;30(7):1388–96. doi:10.1016/j.vaccine.2011.12.009.
167. Madan A, Ferguson M, Sheldon E, Segall N, Chu L, Toma A, Rheault P, Friel D, Soni J, Li P, et al. Immunogenicity and safety of an AS03-adjuvanted H7N1 vaccine in healthy adults: A phase I/II, observer-blind, randomized, controlled trial. *Vaccine.* 2017;35(10):1431–1439. doi:10.1016/j.vaccine.2017.01.054.
168. Esposito S, Marchisio P, Droghetti R, Lambertini L, Faelli N, Bosis S, Tosi S, Begliatti E, Principi N. Influenza vaccination coverage among children with high-risk medical conditions. *Vaccine.* 2006;24(24):5251–5. doi:10.1016/j.vaccine.2006.03.059.
169. CDC. Prevention and Control of Influenza with Vaccines. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. *Morb Mortal Wkly Rep (MMWR).* 2010;59(RR08):1–62.
170. Santos AJ, Kislaya I, Machado A, Nunes B. Beliefs and attitudes towards the influenza vaccine in high-risk individuals. *Epidemiol Infect.* 2017;145(9):1786–1796. doi:10.1017/S0950268817000814.
171. Halasa NB, Savani BN, Asokan I, Kassim A, Simons R, Summers C, Bourgeois J, Clifton C, Vaughan LA, Lucid C, et al. Randomized Double-Blind Study of the Safety and Immunogenicity of Standard-Dose Trivalent Inactivated Influenza Vaccine versus High-Dose Trivalent Inactivated Influenza Vaccine in Adult Hematopoietic Stem Cell Transplantation Patients. *Biol Blood Marrow Transplant.* 2016;22(3):528–35. doi:10.1016/j.bbmt.2015.12.003.
172. Seo YB, Lee J, Song JY, Choi HJ, Cheong HJ, Kim WJ. Safety and immunogenicity of influenza vaccine among HIV-infected adults: Conventional vaccine vs. intradermal vaccine. *Hum Vaccin Immunother.* 2016;12(2):478–84. doi:10.1080/21645515.2015.1076599.

173. Seo YB, Baek JH, Lee J, Song JY, Lee JS, Cheong HJ, Kim WJ. Long-Term Immunogenicity and Safety of a Conventional Influenza Vaccine in Patients with Type 2 Diabetes. *Clin Vaccine Immunol.* 2015;22(11):1160–5. doi:10.1128/CVI.00288-15.
174. Lu Y, Jacobson DL, Ashworth LA, Grand RJ, Meyer AL, McNeal MM, Gregas MC, Burchett SK, Bousvaros A. Immune response to influenza vaccine in children with inflammatory bowel disease. *Am J Gastroenterol.* 2009;104(2):444–53. doi:10.1038/ajg.2008.120.
175. Hakim H, Allison KJ, Van de Velde LA, Tang L, Sun Y, Flynn PM, McCullers JA. Immunogenicity and safety of high-dose trivalent inactivated influenza vaccine compared to standard-dose vaccine in children and young adults with cancer or HIV infection. *Vaccine.* 2016;34(27):3141–3148. doi:10.1016/j.vaccine.2016.04.053.
176. Benchimol EI, Hawken S, Kwong JC, Wilson K. Safety and utilization of influenza immunization in children with inflammatory bowel disease. *Pediatrics.* 2013;131(6):e1811–20. doi:10.1542/peds.2012-3567.
177. Cordero E, Roca-Oporto C, Bulnes-Ramos A, Aydillo T, Gavalda J, Moreno A, Torre-Cisneros J, Montejo JM, Fortun J, Munoz P, et al. TS. Group, Two Doses of Inactivated Influenza Vaccine Improve Immune Response in Solid Organ Transplant Recipients: Results of TRANSGRIPE 1–2, a Randomized Controlled Clinical Trial. *Clin Infect Dis.* 2017;64(7):829–838. doi:10.1093/cid/ciw855.
178. Branagan AR, Duffy E, Albrecht RA, Cooper DL, Seropian S, Parker TL, Gan G, Li F, Zelterman D, Boddupalli CS, et al. Clinical and Serologic Responses After a Two-dose Series of High-dose Influenza Vaccine in Plasma Cell Disorders: A Prospective, Single-arm Trial. *Clin Lymphoma Myeloma Leuk.* 2017;17(5):296–304 e2. doi:10.1016/j.clml.2017.02.025.
179. Saito T, Ohfuji S, Matsumura T, Saito T, Maeda K, Maeda A, Fukushima W, Fujimura H, Sakoda S, Hirota Y. Safety of a Pandemic Influenza Vaccine and the Immune Response in Patients with Duchenne Muscular Dystrophy. *Intern Med.* 2015;54(10):1199–205. doi:10.2169/internalmedicine.54.1186.
180. McManus M, Frangoul H, McCullers JA, Wang L, O’Shea A, Halasa N. Safety of high dose trivalent inactivated influenza vaccine in pediatric patients with acute lymphoblastic leukemia. *Pediatr Blood Cancer.* 2014;61(5):815–20. doi:10.1002/pbc.24863.
181. Tanaka S, Saikusa T, Katafuchi Y, Ushijima K, Ohtsu Y, Tsumura N, Ito Y. Serologic response after vaccination against influenza (A/H1N1)pdm09 in children with renal disease receiving oral immunosuppressive drugs. *Vaccine.* 2015;33(38):5000–4. doi:10.1016/j.vaccine.2015.06.049.
182. Fausto F, Paolo P, Anna O, Carlo S. Excess mortality in Italy: Should we care about low influenza vaccine uptake? *Scand J Public Health.* 2017;1403494817720102.
183. Rizzo C, Rezza G, Ricciardi W. Strategies in recommending influenza vaccination in Europe and US. *Hum Vaccin Immunother.* 2017;0. doi:10.1080/21645515.2017.1367463. [Epub ahead of print].
184. Poland GA, Whitaker JA, Poland CM, Ovsyannikova IG, Kennedy RB. Vaccinology in the third millennium: scientific and social challenges. *Curr Opin Virol.* 2016;17:116–25. doi:10.1016/j.coviro.2016.03.003.
185. Gianchecchi E, Fierabracci A. Gene/environment interactions in the pathogenesis of autoimmunity: new insights on the role of Toll-like receptors. *Autoimmun Rev.* 2015;14(11):971–83. doi:10.1016/j.autrev.2015.07.006.
186. CDC. Influenza (Flu) Vaccine Safety. 2015. <https://www.cdc.gov/flu/protect/vaccine/vaccinesafety.htm>.
187. CDC. Influenza (Flu) Vaccine (Inactivated or Recombinant): What you need to know. 2015.
188. Neuzil KM, Bresee JS, de la Hoz F, Johansen K, Karron RA, Krishnan A, Madhi SA, Mangtani P, Spiro DJ, Ortiz JR. W.H.O.P.P.C.f.N.-G.I. V.A. Group, Data and product needs for influenza immunization programs in low- and middle-income countries: Rationale and main conclusions of the WHO preferred product characteristics for next-generation influenza vaccines. *Vaccine.* 2017;35(43):5734–5737. doi:10.1016/j.vaccine.2017.08.088.
189. WHO. Global Vaccine Action Plan 2011–2020. 2017. [http://www.who.int/immunization/global\\_vaccine\\_action\\_plan/GVAP\\_doc\\_2011\\_2020/en/](http://www.who.int/immunization/global_vaccine_action_plan/GVAP_doc_2011_2020/en/).